CVE:IOT

Innovotech Competitors

C$0.15
-0.01 (-3.23 %)
(As of 04/14/2021 09:38 AM ET)
Add
Compare
Today's Range
C$0.15
Now: C$0.15
C$0.15
50-Day Range
C$0.15
MA: C$0.17
C$0.19
52-Week Range
C$0.10
Now: C$0.15
C$0.30
Volume7,000 shs
Average Volume34,235 shs
Market CapitalizationC$5.83 million
P/E Ratio75.00
Dividend YieldN/A
BetaN/A

Competitors

Innovotech (CVE:IOT) Vs. QPT, CZO, CTX, KNE, GSD, and PAS

Should you be buying IOT stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Innovotech, including Quest PharmaTech (QPT), Ceapro (CZO), Crescita Therapeutics (CTX), Kane Biotech (KNE), Devonian Health Group (GSD), and Pascal Biosciences (PAS).

Quest PharmaTech (CVE:QPT) and Innovotech (CVE:IOT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk.

Valuation & Earnings

This table compares Quest PharmaTech and Innovotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quest PharmaTechC$38,871.00409.98C$109.88 millionC$0.660.15
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00

Quest PharmaTech has higher earnings, but lower revenue than Innovotech. Quest PharmaTech is trading at a lower price-to-earnings ratio than Innovotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Quest PharmaTech and Innovotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quest PharmaTechN/AN/AN/A
InnovotechN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and price targets for Quest PharmaTech and Innovotech, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quest PharmaTech0000N/A
Innovotech0000N/A

Summary

Quest PharmaTech beats Innovotech on 3 of the 5 factors compared between the two stocks.

Ceapro (CVE:CZO) and Innovotech (CVE:IOT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ceapro and Innovotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ceapro0000N/A
Innovotech0000N/A

Profitability

This table compares Ceapro and Innovotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CeaproN/AN/AN/A
InnovotechN/AN/AN/A

Valuation & Earnings

This table compares Ceapro and Innovotech's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CeaproC$16.14 million3.75C$2.56 millionC$0.0323.64
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00

Ceapro has higher revenue and earnings than Innovotech. Ceapro is trading at a lower price-to-earnings ratio than Innovotech, indicating that it is currently the more affordable of the two stocks.

Summary

Ceapro beats Innovotech on 3 of the 5 factors compared between the two stocks.

Crescita Therapeutics (TSE:CTX) and Innovotech (CVE:IOT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.

Earnings & Valuation

This table compares Crescita Therapeutics and Innovotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Crescita TherapeuticsC$15.64 million1.11C$41,296.00C$0.00420.00
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00

Innovotech has lower revenue, but higher earnings than Crescita Therapeutics. Innovotech is trading at a lower price-to-earnings ratio than Crescita Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Crescita Therapeutics and Innovotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Crescita Therapeutics0000N/A
Innovotech0000N/A

Profitability

This table compares Crescita Therapeutics and Innovotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Crescita TherapeuticsN/AN/AN/A
InnovotechN/AN/AN/A

Innovotech (CVE:IOT) and Kane Biotech (CVE:KNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Innovotech and Kane Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00
Kane BiotechC$1.34 million12.95C$-3,801,490.00C($0.04)-4.57

Innovotech has higher earnings, but lower revenue than Kane Biotech. Kane Biotech is trading at a lower price-to-earnings ratio than Innovotech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Innovotech and Kane Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InnovotechN/AN/AN/A
Kane BiotechN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings for Innovotech and Kane Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovotech0000N/A
Kane Biotech0000N/A

Summary

Innovotech beats Kane Biotech on 3 of the 5 factors compared between the two stocks.

Innovotech (CVE:IOT) and Devonian Health Group (CVE:GSD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Innovotech and Devonian Health Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innovotech0000N/A
Devonian Health Group0000N/A

Profitability

This table compares Innovotech and Devonian Health Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InnovotechN/AN/AN/A
Devonian Health GroupN/AN/AN/A

Earnings and Valuation

This table compares Innovotech and Devonian Health Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00
Devonian Health GroupC$1.59 million15.20C$-4,457,184.00C($0.05)-5.42

Innovotech has higher earnings, but lower revenue than Devonian Health Group. Devonian Health Group is trading at a lower price-to-earnings ratio than Innovotech, indicating that it is currently the more affordable of the two stocks.

Summary

Innovotech beats Devonian Health Group on 3 of the 5 factors compared between the two stocks.

Pascal Biosciences (CVE:PAS) and Innovotech (CVE:IOT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Pascal Biosciences and Innovotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pascal Biosciences0000N/A
Innovotech0000N/A

Profitability

This table compares Pascal Biosciences and Innovotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pascal BiosciencesN/AN/AN/A
InnovotechN/AN/AN/A

Earnings and Valuation

This table compares Pascal Biosciences and Innovotech's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pascal BiosciencesN/AN/AN/AC($0.02)-4.32
InnovotechC$1.04 million5.60C$77,748.00C$0.0075.00

Innovotech has higher revenue and earnings than Pascal Biosciences. Pascal Biosciences is trading at a lower price-to-earnings ratio than Innovotech, indicating that it is currently the more affordable of the two stocks.

Summary

Innovotech beats Pascal Biosciences on 3 of the 3 factors compared between the two stocks.


Innovotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
QPT
Quest PharmaTech
0.8$0.10-10.5%C$21.76 millionC$38,871.000.15High Trading Volume
Gap Down
CZO
Ceapro
0.6$0.78-0.0%C$21.65 millionC$16.14 million23.64Gap Up
CTX
Crescita Therapeutics
0.6$0.84-1.2%C$17.34 millionC$15.64 million420.00News Coverage
KNE
Kane Biotech
0.4$0.16-0.0%C$14.12 millionC$1.34 million-4.57Gap Down
GSD
Devonian Health Group
0.5$0.26-3.8%C$13.96 millionC$1.59 million-5.42Gap Up
PAS
Pascal Biosciences
0.6$0.10-5.3%C$12.70 millionN/A-4.32Gap Down
NSP
Naturally Splendid Enterprises
0.6$0.06-8.3%C$11.06 millionC$2.03 million-1.40Gap Up
MPH
Medicure
0.7$1.58-1.3%C$10.80 millionC$12.71 million-1.02
BTI
Bioasis Technologies
0.7$0.39-1.3%C$10.16 millionC$4.12 million35.00
HEM
Hemostemix
0.6$0.45-2.2%C$9.07 millionN/A-2.68Gap Down
ICO
iCo Therapeutics
0.5$0.11-0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.37-1.4%C$6.94 millionC$5.60 million6.76News Coverage
Gap Down
BCT
BriaCell Therapeutics
0.5$4.00-12.5%C$4.48 millionN/A-1.29High Trading Volume
RVV
Revive Therapeutics
0.5$0.08-12.5%C$3.62 millionN/A-3.64High Trading Volume
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04-71.4%C$1.54 millionN/A-0.30Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03-16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01-0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Down
HALO
Halozyme Therapeutics
1.3$45.95-3.2%C$0.00C$267.59 million50.49News Coverage
LTY
Liberty Biopharma
0.6$2.00-100.0%C$0.00N/A-12.66News Coverage
Gap Down
MMJ
Matica Enterprises
0.5N/AN/AC$0.00N/A0.00High Trading Volume
SCYB
Scythian Biosciences
0.5$3.49-6.3%C$0.00N/A0.00High Trading Volume
ABCN
VIVO Cannabis
0.6$1.32-5.3%C$0.00N/A0.00Gap Down
VP
Vodis Pharmaceuticals
0.6N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.